article thumbnail

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

DAIC

As the pioneer in valve innovation for more than 60 years, Edwards believes it is uniquely positioned to lead this next frontier of aortic valve disease treatment. A CMS national coverage determination is expected in early 2025. JenaValve presented positive results of its U.S.

article thumbnail

Edwards Acquires JenaValve and Endotronix, Expands into Aortic Regurgitation and Heart Failure

CardiacWire

Edwards Lifesciences is going all-in on structural heart and heart failure, acquiring aortic valve-maker JenaValve Technology and implantable heart failure monitor company Endotronix for $1.2B and up to $445M in milestone payments.

article thumbnail

New Legislation Speeds Progress on Patient Access to New Technologies

Society of Thoracic Surgeons - Technology

For example, we have a lot of meaningful data on outcomes from CABG procedures and transcatheter aortic valve replacement in the short term. Speir, MD, Chair of the STS Council on Health Policy and Relationships. Download the PDF version Advocacy Quality Improvement Technology